Nivolumab induces dynamic alterations in CD8 T-cell function and TIM-3 expression when used to treat relapsed acute myeloid leukemia after allogeneic stem cell transplantation

Trial registration: ClinicalTrials.gov identifier: NCT03146468.Relapse of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (alloSCT) is a major cause of mortali...